Serina Therapeutics, Inc.
Current- Director 2026 to present
Skip to record
Executive record
Alpha ID: alpha:person:randall-moreadith-m-d-ph-dVersion: public-0As of: 2026-10-04
Not yet claimed7 published Claims3 sources
- Director
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Dr. Moreadith served as Legacy Serina's President and Chief Executive Officer from September 2010 to March 2024. He has extensive experience in drug development, having served as Chief Development Officer at Nektar Therapeutics, Chief Medical Officer at Cardium Therapeutics and Renovis, and co-founder of ThromboGenics. He holds an M.D. from Duke University and Ph.D. from Johns Hopkins University.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Boards
Claims
Executive career
- 2026 to end not publishedExecutive title: Chief Development Officer · Organization not publishedSER DEF 14A executive officers
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
SER DEF 14A executive officers
sec filing · Source published: Apr 27, 2026 · Retrieved: May 16, 2026
Supports 5 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Executive company: Executive at Serina Therapeutics, Inc. · Claim reviewed: May 16, 2026
- Executive title: Executive title: Chief Development Officer · Claim reviewed: May 16, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026
Open source
sec proxy · Source published: Apr 27, 2026 · Retrieved: Sep 2, 2026
Supports 1 claim
- Professional Role: Director at Serina Therapeutics, Inc. · Claim reviewed: May 16, 2026
Open source
public source · Source published: Date unavailable · Retrieved: Date unavailable
Supports 1 claim
- Board membership: Serves on the board of Serina Therapeutics, Inc. · Claim reviewed: May 16, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-04
- Biography
- published
- Board service
- published
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope